The drug is now also approved for obstructive sleep apnea in adults with obesity, where it cut the apnea-hypopnea index by about half in the SURMOUNT-OSA trial
This piece comes from the PlexusDx Education Hub, our library on GLP-1 therapies, weight management protocols, and the genetics beneath them
It can help you lose pounds and maintain a healthy figure
- This study investigated the association of semaglutide 2.4 mg with major adverse cardiovascular events among individuals with overweight/obesity without diabetes who had risk factors for atherosclerotic cardiovascular disease.- This study investigated the association of semaglutide 2.4 mg with major adverse cardiovascular events among individuals with overweight/obesity without diabetes who had risk factors for atherosclerotic cardiovascular disease.- 48,184 patients initiating semaglutide 2.4 mg were propensity-score matched 1:2 to those not on semaglutide 2.4 mg (96,368 individuals).- In this study, semaglutide 2.4 mg was associated with a lower risk of incident major adverse cardiovascular events and heart failure composite outcomes.- Exploratory analyses further demonstrated consistent lower risks of obesity-related outcomes, including incident type 2 diabates, major adverse kidney events, acute kidney injury, major obesity-related adverse events, and all-cause hospitalization.Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE primary prevention study (open access) doi.org/10.1016/j.ajpc
These include lean protein, fruits, vegetables, whole grains, and healthy fats
You should not use Zepbound if you are pregnant
